BostonGene, a pioneer in AI-driven molecular and immune profiling solutions, has secured four prestigious Clinical Trials Arena Excellence Awards.
In an announcement made today, BostonGene revealed its triumph in the categories of Business Expansion, Innovation, and Product Launches, underlining its dedication to advancing precision diagnostics and enhancing patient outcomes.
GlobalData recognition
The Clinical Trials Arena Excellence Awards, organized by GlobalData, recognized BostonGene’s remarkable achievements amidst stiff competition. GlobalData, renowned for its comprehensive analysis utilizing researchers, journalists, and artificial intelligence, acknowledged BostonGene’s contribution to personalized therapies and improved patient care.
Tina Ross, Awards Manager at Clinical Trials Arena Excellence Awards, lauded BostonGene’s groundbreaking work, particularly in the Innovation category. She emphasized the transformative impact of BostonGene’s AI-driven diagnostic technologies in accelerating drug development and treatment selection.
Innovation in molecular diagnostics
BostonGene clinched two awards in the Innovation category, cementing its position as a frontrunner in molecular diagnostics. The accolades were bestowed upon BostonGene for its revolutionary Kassandra™ machine learning algorithm for bulk RNA-seq cell type deconvolution and its proprietary AI-driven clinical trial-matching algorithm. These innovations not only signify BostonGene’s commitment to cutting-edge research but also its ability to provide invaluable insights to healthcare providers and pharmaceutical companies.
BostonGene’s Product Launches award commends the development of a new Liquid Biopsy assay, a CLIA-certified and CAP-accredited test capable of detecting clinically actionable gene alterations. This assay plays a crucial role in predicting treatment response and monitoring disease progression, thereby empowering clinicians with actionable data to tailor treatment strategies for individual patients.
Moreover, BostonGene’s Business Expansion award highlights its recent launch of CLIA-certified and CAP-accredited Liquid Biopsy, Immunoprofiling, and Spatial Proteomics solutions. These platforms, coupled with the Tumor PortraitTM next-generation sequencing-based test, offer a comprehensive view of each patient’s disease profile, facilitating precision oncology efforts across discovery, translational, and clinical domains.
Andrew Feinberg’s perspective
Andrew Feinberg, President and CEO of BostonGene, expressed profound gratitude for the recognition received from GlobalData. He emphasized that these awards not only acknowledge past accomplishments but also underscore BostonGene’s momentum in leveraging AI-driven technologies to drive innovation in precision medicine.
BostonGene is dedicated to providing transformative, AI-integrated molecular analytics and biomarker discovery to enhance the lives of patients with cancer and immune-related diseases. Through its concierge-service model, BostonGene offers customized solutions prioritized for real-world impact, optimizing standard-of-care therapies and accelerating research efforts. BostonGene’s comprehensive tests provide a personalized roadmap for therapeutic decision-making, incorporating analyses of the immune microenvironment, actionable mutations, biomarkers, and recommended therapies.
BostonGene’s success at the Clinical Trials Arena Excellence Awards underscores its commitment to advancing precision diagnostics and improving patient outcomes. With a focus on innovation, product launches, and business expansion, BostonGene continues to lead the way in harnessing AI-driven technologies to revolutionize personalized medicine.
